Trials / Completed
CompletedNCT05274334
Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University Children's Hospital Basel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This proof of concept- study is to measure de novo lipogenesis (DNL) non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.
Detailed description
The study objective is to measure the DNL by ingestion of a single oral dose of 70% 2H2O at 2 g/kg body-water. The subjects will consume a Yoghurt consisting of 300g of 'Excellence Joghurt Nature gezuckert' which contains 410 Kcal, 28g fat, 34g carbohydrates and 9g protein. The exhaled air of the subjects will be measured several times per hour to analyse de novo lipogenesis (DNL) non-invasive by deuterium resolved mass spectrometry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Assessment of de novo lipogenesis non-invasively in exhaled breath | 1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements. 2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish. 3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water. 4. Participants execute several exhalation sets over time. 5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert. 6. Participants execute several exhalation sets over time. 7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded. |
Timeline
- Start date
- 2022-05-11
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2022-03-10
- Last updated
- 2022-11-04
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05274334. Inclusion in this directory is not an endorsement.